Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?

被引：0
|
作者：
Pier Paolo M. Berton Giachetti
Giuseppe Curigliano
机构：
[1] Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS),Division of Early Drug Development for Innovative Therapy, European Institute of Oncology
[2] University of Milan,Department of Oncology and Hemato
来源：
Nature Reviews Clinical Oncology | 2024年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Recent results from the phase III PHILA trial demonstrate a benefit in terms of progression-free survival derived from the addition of pyrotinib to first-line chemotherapy plus trastuzumab in patients with metastatic HER2-positive breast cancer. Dual HER2 blockade with pyrotinib and trastuzumab is an effective therapeutic strategy but might increase the risk of gastrointestinal toxicity; therefore, the risk-to-benefit ratio should be carefully evaluated.
引用
收藏
页码：171 / 172
页数：1
相关论文
共 50 条
  • [1] Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Giachetti, Pier Paolo M. Berton
    Curigliano, Giuseppe
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (03) : 171 - 172
  • [2] An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer
    Cardoso, Fatima
    Canon, Jean-Luc
    Amadori, Dino
    Aldrighetti, Daniela
    Machiels, Jean-Pascal
    Bouko, Yasmina
    Verkh, Lev
    Usari, Tiziana
    Kern, Kenneth A.
    Giorgetti, Carla
    Dirix, Luc
    BREAST, 2012, 21 (06): : 716 - 723
  • [3] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [4] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [5] Evaluation of first-line trastuzumab in combination with epirubicin/cyclophosphamide for patients with HER2-positive metastatic breast cancer.
    Unich, M.
    Tjulandin, S.
    Jonat, W.
    Meerpohl, H.
    Lichinitser, M.
    Manikhas, G. M.
    Janicke, F.
    Muscholl, M.
    Pausehinger, M.
    Thomssen, C.
    Leide, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S185 - S186
  • [6] Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
    Crown, J.
    Kennedy, M. J.
    Tresca, P.
    Marty, M.
    Espie, M.
    Burris, H. A.
    DeSilvio, M.
    Lau, M. R.
    Kothari, D.
    Koch, K. M.
    Dieras, V.
    ANNALS OF ONCOLOGY, 2013, 24 (08) : 2005 - 2011
  • [7] Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial
    Zheng, Yabing
    Cao, Wen-Ming
    Shao, Xiying
    Shi, Yanxia
    Cai, Li
    Chen, Wenyan
    Liu, Jian
    Shen, Peng
    Chen, Yiding
    Wang, Xian
    Li, Huiping
    Li, Man
    Chen, Zhanhong
    Wang, Xiaojia
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [8] Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial
    Yabing Zheng
    Wen-Ming Cao
    Xiying Shao
    Yanxia Shi
    Li Cai
    Wenyan Chen
    Jian Liu
    Peng Shen
    Yiding Chen
    Xian Wang
    Huiping Li
    Man Li
    Zhanhong Chen
    Xiaojia Wang
    Nature Communications, 14
  • [9] First-line pyrotinib plus trastuzumab and nab-paclitaxel for patients with HER2-positive advanced breast cancer
    Xie, Hui
    Li, Wei
    Yao, Yufeng
    Ni, Sujie
    Yi, Tongbo
    Cheng, Jinling
    Fang, Qi
    Zhang, Lei
    Zhou, Jun
    Wu, Xiaohong
    Wang, Chunbin
    Zhang, Yanan
    Qin, Jianwei
    Shao, Qing
    Zhao, Tao
    Huang, Xiaohong
    Xu, Lingyun
    CANCER RESEARCH, 2022, 82 (04)
  • [10] Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
    Lee, Yong-Pyo
    Lee, Min-Sang
    Kim, HongSik
    Kim, Ji-Yeon
    Ahn, Jin Seok
    Im, Young-Hyuck
    Park, Yeon Hee
    CANCER RESEARCH AND TREATMENT, 2022, 54 (04): : 1130 - 1137
12345